Pirfenidone Tablet
Product Images NDC 51407-914

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Pirfenidone (NDC 51407-914). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-913-27ol (Pirfenidone 267 mg)

Label for Pirfenidone Tablets USP, 267 mg strength, containing 270 tablets. The label highlights the active ingredient amount per film-coated tablet, storage instructions, and safety warnings. It includes the NDC 51407-913-27 and states it is marketed by GSMS, Incorporated in Camarillo, California, USA.*

FDA Label Image

51407-914-90ol (Pirfenidone 801 mg)

Label for Pirfenidone Tablets USP 801 mg oral tablets, marketed by GSMS Incorporated. The label shows a package of 90 tablets, includes a NDC barcode, and instructs dispensing with patient information. Storage instructions and warnings to keep out of reach of children are also present.*

FDA Label Image

Figure1.jpg (Figure1)

This graph shows a cumulative distribution curve depicting the absolute change in percent forced vital capacity (%FVC) from baseline to week 52 for patients taking Pirfenidone compared to placebo. The x-axis measures absolute change in %FVC, ranging from -30% to +10%, with worsening decline on the left and no decline or increase on the right. The y-axis shows the percentage of patients, from 0% to 100%, with Pirfenidone and placebo groups represented by solid black and dotted gray lines, respectively.*

FDA Label Image

Figure2.jpg (Figure2)

A line graph depicting mean change in forced vital capacity (FVC) over 52 weeks comparing Pirfenidone and placebo groups. The x-axis represents weeks (0, 13, 26, 39, 52), and the y-axis shows mean change in FVC (mL). Pirfenidone group (n=278) has a less steep decline than placebo group (n=277) over time.*

FDA Label Image

Figure3.jpg (Figure3)

A Kaplan-Meier survival curve comparing the percentage of patients alive over time in weeks for Pirfenidone versus placebo groups. The chart shows survival rates from 0 to 120 weeks with patient counts at risk listed below. Pirfenidone and placebo groups are represented by solid and dashed lines respectively, with a hazard ratio and 95% confidence interval provided.*

FDA Label Image

Structure.jpg (Structure)

Chemical structure of pirfenidone, showing a fused aromatic ring system with a methyl group, nitrogen atom, and a carbonyl group, linked to a phenyl group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.